Mediterranean diet enhances tirzepatide benefits for visceral fat and insulin resistance beyond weight loss alone | Research

The takeaway

In 53 patients, combining tirzepatide with high Mediterranean diet adherence produced greater reductions in visceral adiposity and insulin resistance than the drug alone, with PREDIMED scores increasing by 3.2 points over 3 months.

Diet quality amplifies drug effect
Higher Mediterranean diet adherence independently predicted greater visceral fat reduction and insulin improvement on tirzepatide

What the researchers found

After 3 months of tirzepatide, significant reductions in weight, BMI, WC, WtHR, BRI, and VAI (all p<0.05). PREDIMED scores increased +3.2 points (p<0.001). Higher Mediterranean diet adherence independently associated with lower insulin, improved HOMA, and greater VAI reduction.

Why it matters

Clinical trials of GLP-1 drugs rarely account for diet quality. This study provides first evidence that what patients eat while on tirzepatide matters—Mediterranean diet adherence specifically enhances visceral fat reduction and metabolic improvement beyond drug effects alone.

The numbers in context

53 patients with BMI >= 27-30. Tirzepatide 2.5 mg/week for 1 month then 5.0 mg/week. 3-month follow-up. Assessed BMI, waist circumference, WtHR, BRI, ABSI, VAI. PREDIMED score for diet quality. Significant reductions in weight and adiposity indices.

How the study worked

Prospective real-world study of 53 overweight/obese patients on tirzepatide (2.5→5 mg/week) with Mediterranean diet counseling, assessed at baseline and 3 months with anthropometric, adiposity, and biochemical measures.

Who was studied

Adults with overweight/obesity starting tirzepatide

What this study cannot tell us

Small sample (n=53). No control group without Mediterranean diet. Short 3-month follow-up. Observational design cannot confirm causation between diet and enhanced outcomes. Self-reported dietary adherence.

How to read the evidence

Small prospective observational study. Provides exploratory evidence for diet-drug synergy but limited by sample size and absence of control group.

When this study was published

Published in 2025; one of the first studies to examine diet quality's interaction with GLP-1/GIP dual agonist therapy.

The bigger picture

This study challenges the implicit assumption that GLP-1 drugs work independently of lifestyle. By showing that diet quality amplifies pharmacological benefits, it supports integrated treatment approaches combining medication with specific dietary patterns.

Questions still open

Would other dietary patterns (low-carb, plant-based) show similar synergy with tirzepatide?
Does Mediterranean diet adherence improve long-term weight maintenance on GLP-1 drugs?
Should dietary counseling be a standard co-prescription with GLP-1 agonists?

Common questions

Does what you eat matter when taking tirzepatide?

Yes, this study found that patients who followed a Mediterranean diet more closely while taking tirzepatide had greater improvements in visceral fat and insulin resistance than those with lower diet adherence, even beyond the drug's direct weight loss effects.

What is the Mediterranean diet?

The Mediterranean diet emphasizes fruits, vegetables, whole grains, legumes, nuts, olive oil, and fish while limiting processed foods, red meat, and added sugars. Adherence was measured using the validated PREDIMED score, which increased significantly in patients receiving dietary counseling alongside tirzepatide.

Read the original research

Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.

Frontiers in endocrinology, 16, 1700894

View on PubMed ↗Publisher’s paper ↗

Citation

Paternò, Valentina; Geraci, Giulio; Piticchio, Tommaso; Le Moli, Rosario; Burgio, Stefano; Costanzo, Gabriele; Sambataro, Gianluca; Baratta, Roberto; Barbagallo, Federica; Pallotti, Francesco. (2025). Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.. Frontiers in endocrinology, 16, 1700894. https://doi.org/10.3389/fendo.2025.1700894